AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

IMMUTEP LTD

0.048

-0.002-4.00%

Volume:4.22M

Turnover:205.61K

Market Cap:70.74M

PE:-0.84

High:0.050

Open:0.049

Low:0.048

Close:0.050

52wk High:0.470

52wk Low:0.028

Shares:1.47B

Float Shares:1.23B

Volume Ratio:1.39

T/O Rate:0.34%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.057

EPS(LYR):-0.042

ROE:-77.31%

ROA:-40.89%

PB:1.15

PE(LYR):-1.14

Loading ...

Overview Company News Filings

Immutep director Peter Andrew Meyers files initial beneficial ownership statement

BRIEF-Immutep Discontinues Phase III Tacti-004 Study In Non-Small Cell Lung Cancer

Immutep Ltd - Discontinues Phase Iii Tacti-004 Study in Non-Small Cell Lung Cancer

THOMSON REUTERS

Immutep Ltd - Estimates Review Process Could Extend Into Q3 2026

THOMSON REUTERS

Immutep files initial beneficial ownership statement for Chief Medical Officer Stephan Winckels

Immutep files Form 3 as Chief Development Officer Christian Mueller reports beneficial ownership

ASX Runners of the Week: Immutep, Blue Star Helium & Patagonia

The West Australian

Immutep Says JPMorgan Chase Reduces Stake

MT Newswires Live

Immutep Says Bank of New York Mellon Increases Stake

MT Newswires Live

Rosen Law Firm probes potential securities class action over Immutep disclosures

Immutep Reports Progress From Phase I Study of Lag-3 Agonist for Autoimmune Diseases

THOMSON REUTERS

Immutep Says Insignia Financial Ceases to be a Substantial Shareholder

MT Newswires Live

Immutep Completes Single Ascending Dose Portion of Phase One Autoimmune Disease Therapy Candidate Study; Shares Rise 5%

MT Newswires Live

Immutep completes Phase I single ascending dose trial of IMP761 up to 14 mg/kg

Down 87% since Friday, why is this ASX 300 healthcare stock sliding again today?

How does Bell Potter rate these ASX healthcare stocks

BUZZ - US STOCKS ON THE MOVE-Kyivstar Group, Applied Materials, Tevogen Bio

Dr. Reddy's SA Halts TACTI-004 Phase III Study Enrollment

BRIEF-Dr Reddy's Says IDMC Recommends Discontinuation Of TACTI-004 Phase III Trial After Interim Futility Analysis

Immutep Ltd - Trial Discontinued for Futility Based on Safety and Efficacy Data Review

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/IMM.AU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMM.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","market":"AU","secType":"STK","nameCN":"IMMUTEP LTD","latestPrice":0.048,"timestamp":1788156720000,"preClose":0.05,"halted":0,"volume":4218452,"delay":0,"changeRate":-0.040000000000000036,"nameEN":"IMMUTEP LTD","floatShares":1228247159,"shares":1473721306,"eps":-0.057294,"marketStatus":"Not Yet Opened","change":-0.002,"latestTime":"08-31 16:12:00 AEST","open":0.049,"high":0.05,"low":0.048,"amount":205609,"amplitude":0.04,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.057294,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1788220800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.05,"openAndCloseTimeList":[[1788134400000,1788156000000]],"volumeRatio":1.3884976774797497,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"IMM.AU","preClose":0.048,"auctionPrice":0.048,"auctionVolume":36974,"auctionTime":1788218967310,"referenceTime":1788172203092,"auction":1,"marketStatus":"盘前竞价","timestamp":1788218967310}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","floatShares":1228247159,"roa":"-40.89%","roe":"-77.31%","lyrEps":-0.042199,"volumeRatio":1.3884976774797497,"shares":1473721306,"dividePrice":0,"high":0.05,"amplitude":0.04,"preClose":0.05,"low":0.048,"week52Low":0.028,"pbRate":"1.15","psRate":"3.08","week52High":0.47,"institutionHeld":0,"latestPrice":0.048,"eps":-0.057294,"divideRate":0,"volume":4218452,"delay":0,"ttmEps":-0.057294,"open":0.049,"prevYearClose":0.415,"prevWeekClose":0.05,"prevMonthClose":0.048,"prevQuarterClose":0.053,"fiveDayClose":0.053,"twentyDayClose":0.046,"sixtyDayClose":0.048,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMM.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-06-05","symbol":"IMM.AU","defaultRemindTime":1717545600000,"type":"split","dateTimestamp":1717509600000,"forFactor":948148,"toFactor":1000000,"ratio":0.9481480000000001}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMM.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMM.AU\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2625399389","title":"Immutep director Peter Andrew Meyers files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2625399389","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625399389?lang=en_us&edition=fundamental","pubTime":"2026-04-08 09:29","pubTimestamp":1775611793,"startTime":"0","endTime":"0","summary":"Immutep director Peter Andrew Meyers filed an initial beneficial ownership statement showing 4,052,173 ordinary shares held directly as of March 18, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 07, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL5CrYXc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625998707","title":"BRIEF-Immutep Discontinues Phase III Tacti-004 Study In Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2625998707","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625998707?lang=en_us&edition=fundamental","pubTime":"2026-04-08 09:24","pubTimestamp":1775611490,"startTime":"0","endTime":"0","summary":"BRIEF-Immutep Discontinues Phase III Tacti-004 Study In Non-Small Cell Lung CancerApril 8 (Reuters) - Immutep Ltd IMM.AX:DISCONTINUES PHASE III TACTI-004 STUDY IN NON-SMALL CELL LUNG CANCERESTIMATES R","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nFWN40Q17Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625996751","title":"Immutep Ltd - Discontinues Phase Iii Tacti-004 Study in Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2625996751","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625996751?lang=en_us&edition=fundamental","pubTime":"2026-04-08 08:06","pubTimestamp":1775606815,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nFWN40Q17Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMM.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625675489","title":"Immutep Ltd - Estimates Review Process Could Extend Into Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2625675489","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625675489?lang=en_us&edition=fundamental","pubTime":"2026-04-08 08:06","pubTimestamp":1775606815,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nFWN40Q17Z:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624594703","title":"Immutep files initial beneficial ownership statement for Chief Medical Officer Stephan Winckels","url":"https://stock-news.laohu8.com/highlight/detail?id=2624594703","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624594703?lang=en_us&edition=fundamental","pubTime":"2026-04-01 18:21","pubTimestamp":1775038871,"startTime":"0","endTime":"0","summary":"Immutep initial Form 3 showed Chief Medical Officer Stephan Karel Gerard Winckels held 92,935 ordinary shares as of March 18, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL3jK9sr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624594974","title":"Immutep files Form 3 as Chief Development Officer Christian Mueller reports beneficial ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2624594974","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624594974?lang=en_us&edition=fundamental","pubTime":"2026-04-01 18:11","pubTimestamp":1775038296,"startTime":"0","endTime":"0","summary":"Immutep Chief Development Officer Christian Mueller reported direct ownership of 3.77 million ordinary shares in an initial Form 3 filing dated 03/18/2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL2YGvfv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620077912","title":"ASX Runners of the Week: Immutep, Blue Star Helium & Patagonia","url":"https://stock-news.laohu8.com/highlight/detail?id=2620077912","media":"The West Australian","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620077912?lang=en_us&edition=fundamental","pubTime":"2026-03-20 06:10","pubTimestamp":1773958210,"startTime":"0","endTime":"0","summary":"The Bulls N’ Bears ASX Runner of the Week is… Immutep. In a slightly perverse twist, the oncology mid-cap bounced hard from last week’s 90 per cent drop, gaining 53 per cent after a brutal sell-off. ","market":"nz","thumbnail":"https://images.thewest.com.au/publication/C-22008191/f3ba145e5bde0aa97d4b38a2ae55d7e52f82c4d9.jpg","type":0,"news_type":0,"thumbnails":["https://images.thewest.com.au/publication/C-22008191/f3ba145e5bde0aa97d4b38a2ae55d7e52f82c4d9.jpg"],"rights":{"source":"thewest_stock","url":"https://thewest.com.au/business/bulls-n-bears/asx-runners-of-the-week-immutep-blue-star-helium-patagonia--c-22008191","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thewest.com.au/business/bulls-n-bears/asx-runners-of-the-week-immutep-blue-star-helium-patagonia--c-22008191","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thewest_stock","symbols":["IMM.AU","BK7095","BK7067","DUG","BK7142","PL3.AU","XOP","BK4570","BNL.AU","BK7508","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2620638274","title":"Immutep Says JPMorgan Chase Reduces Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2620638274","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620638274?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:44","pubTimestamp":1773956688,"startTime":"0","endTime":"0","summary":"Immutep (ASX:IMM) received notice that JPMorgan Chase and its affiliates decreased their holdings in the company to 5.83% from 7.49%, according to a Friday filing with the Australian bourse.JPMorgan Chase and its affiliates now own 85.9 million shares in the company, the filing said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","LU1670628061.USD","JPM","LU1267930490.SGD","LU2381873111.SGD","LU2505996509.AUD","LU2237443895.HKD","IE00BBT3K403.USD","BK7508","IE0034235188.USD","LU1894683264.USD","LU0203345920.USD","LU0496365809.HKD","SG9999002232.USD","LU1145028129.USD","LU1720051017.SGD","LU0345770308.USD","LU0942090050.USD","LU0310799852.SGD","LU2237443978.SGD","IE00BJTD4V19.USD","LU2505996681.GBP","LU0640476718.USD","LU1988902786.USD","IMM.AU","BK4585","LU2054465674.USD","LU2237443622.USD","LU0170899867.USD","IE0034235295.USD","IE00B1XK9C88.USD","LU2552382215.SGD","LU1084165304.USD","LU0417517546.SGD","IE00B775SV38.USD","LU1032466523.USD","LU0006306889.USD","LU0048584097.USD","IE00BZ1G4Q59.USD","LU0211331839.USD","IE000M9KFDE8.USD","IE00BN8TJ469.HKD","JPMO","LU0211328371.USD","LU2746668461.USD","IE0034235303.USD","LU0345769128.USD","LU0323591593.USD","IE00BDCRKT87.USD","LU0265550946.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620746812","title":"Immutep Says Bank of New York Mellon Increases Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2620746812","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620746812?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:44","pubTimestamp":1773956658,"startTime":"0","endTime":"0","summary":"Immutep  received notice that Bank of New York Mellon and its affiliated entities increased their holdings in the company to 20.08% from 19.04%, according to a Friday filing with the Australian bourse.Bank of New York Mellon and its affiliates now own about 296 million shares in the company, the filing said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK","BK4559","LU0648001328.SGD","BK7067","LU1699723380.USD","BK4135","LU0980610538.SGD","BK7508","LU0130517989.USD","IMM.AU","LU0477156953.USD","LU0130102774.USD","LU1201861249.SGD","BK4588","BK4585","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620275803","title":"Rosen Law Firm probes potential securities class action over Immutep disclosures","url":"https://stock-news.laohu8.com/highlight/detail?id=2620275803","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620275803?lang=en_us&edition=fundamental","pubTime":"2026-03-20 03:07","pubTimestamp":1773947236,"startTime":"0","endTime":"0","summary":"Rosen Law Firm said it is investigating potential securities claims on behalf of Immutep shareholders over allegations of materially misleading business information.The investigation follows Immutep’s announcement that an independent data monitoring committee recommended discontinuing the TACTI-004 Phase III trial of eftilagimod alfa in first-line non-small cell lung cancer after an interim futility analysis.After the announcement, Immutep’s ADR fell $2.28 to $0.48, a decline of 82.6%.The firm said it is preparing a securities class action seeking recovery of investor losses.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDLbqrQ9p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999014039.USD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","SG9999014013.SGD","SG9999014021.USD","BK4112","IE00BN0W2V16.EUR","BK7508","LU2210149790.SGD","IE00BKPKM429.USD","NDAQ","LU2210150020.SGD","BK7067","LU2095319765.USD","IMM.AU","SG9999014005.SGD","BK4585","IE00B3QW5Z07.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620247976","title":"Immutep Reports Progress From Phase I Study of Lag-3 Agonist for  Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2620247976","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620247976?lang=en_us&edition=fundamental","pubTime":"2026-03-19 20:00","pubTimestamp":1773921604,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nTUA4SLSWY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620389215","title":"Immutep Says Insignia Financial Ceases to be a Substantial Shareholder","url":"https://stock-news.laohu8.com/highlight/detail?id=2620389215","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620389215?lang=en_us&edition=fundamental","pubTime":"2026-03-19 12:40","pubTimestamp":1773895230,"startTime":"0","endTime":"0","summary":"Immutep  received notice that Insignia Financial  and its subsidiaries are no longer substantial holders of the company from March 13, according to a Thursday Australian bourse filing.Insignia Financial and its subsidiaries became a substantial holder of the company on May 26, 2023, with a 5.193% total voting power, an earlier filing showed.Immutep's shares rose around 2% in recent Thursday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7062","IMM.AU","BK7508","IFL.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620292812","title":"Immutep Completes Single Ascending Dose Portion of Phase One Autoimmune Disease Therapy Candidate Study; Shares Rise 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620292812","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620292812?lang=en_us&edition=fundamental","pubTime":"2026-03-19 09:30","pubTimestamp":1773883807,"startTime":"0","endTime":"0","summary":"Immutep  completed the single ascending dose portion of its first-in-human phase one study evaluating its IMP761 therapy candidate, with dosing up to 14 milligrams per kilogram, according to a Thursday Australian bourse filing.The therapy candidate was well tolerated across all dose levels, and no safety concerns or dose-limiting toxicities were observed. The study is currently progressing in the multiple ascending dose portion, which is expected to be completed in the September quarter. This portion is evaluating the pharmacokinetics and safety of IMP761 across two dose levels.IMP761 is a LAG-3 agonist antibody that enhances the physiological inhibitory function of LAG-3 on T-cell receptor signaling, potentially suppressing pathogenic T-cell responses in autoimmune diseases.Its shares jumped 5% in recent trading on Thursday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMM.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620429419","title":"Immutep completes Phase I single ascending dose trial of IMP761 up to 14 mg/kg","url":"https://stock-news.laohu8.com/highlight/detail?id=2620429419","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620429419?lang=en_us&edition=fundamental","pubTime":"2026-03-19 09:19","pubTimestamp":1773883191,"startTime":"0","endTime":"0","summary":"Immutep reported progress from its placebo-controlled, double-blind first-in-human Phase I study of IMP761, a LAG-3 agonist antibody being evaluated in healthy participants. The company said it completed the single ascending dose portion with dosing up to 14 mg/kg and reported no dose-limiting toxicities to date. Immutep said the study is now in the multiple ascending dose portion, with completion expected in Q3 2026. The Phase I results are scheduled to be presented at the EULAR congress on 4 June 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on March 19, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL2F2TB9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620962162","title":"Down 87% since Friday, why is this ASX 300 healthcare stock sliding again today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2620962162","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620962162?lang=en_us&edition=fundamental","pubTime":"2026-03-19 07:55","pubTimestamp":1773878133,"startTime":"0","endTime":"0","summary":"S&P/ASX 300 Index  healthcare stock Immutep Ltd  has been on a decidedly wild ride these past four trading days.After entering a trading halt on Monday, 9 March, Immutep shares resumed trading last Friday. And by the time the closing bell sounded, the Immutep share price had crashed a very painful 88.6%.Investors were overheating their sell buttons on the day, after the ASX 300 healthcare stock reported that the Phase III lung cancer study of its eftilagimod alfa  product had been discontinued.\"We are very disappointed and surprised with the outcome of the futility analysis, in light of efti's performance in every other clinical trial,\" Immutep CEO Marc Voigt said at the time.On Monday, bargain hunters swooped in, sending the Immutep share price up 35.6% by close. But a lot of those gains evaporated again on Tuesday, with shares closing the day down a sharp 16.4%.See what I mean about a 'decidedly wild ride'?Immutep said it will present the results of the phase I trial at the European ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/19/down-87-since-friday-why-is-this-asx-300-healthcare-stock-sliding-again-today/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/19/down-87-since-friday-why-is-this-asx-300-healthcare-stock-sliding-again-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","IMM.AU","XKO.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620792448","title":"How does Bell Potter rate these ASX healthcare stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2620792448","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620792448?lang=en_us&edition=fundamental","pubTime":"2026-03-17 13:51","pubTimestamp":1773726698,"startTime":"0","endTime":"0","summary":"Bell Potter has been running the rule over a number of small-cap ASX healthcare stocks this week.Let's see what the broker is saying about these speculative stocks.Immutep is a clinical-stage biopharmaceutical company focused on developing novel LAG3 immunotherapy for cancer and autoimmune disease.Its shares were sold off this month after its lead drug, Efti, failed the futility analysis in its global Phase 3 trial in non-small cell lung cancer. Bell Potter notes that this \"is a bitterly disappointing and surprising outcome considering the strength of the company's prior Phase 1 and Phase 2 lung cancer data.\". As a result, it has downgraded its shares to a speculative hold rating with a 7 cents price target . It said:. And thanks to its recent $600 million capital raise, PYC has the benefit of >$700 million in cash, with runway into at least 2030 according to the broker. As a result, Bell Potter believes the company is \"incredibly well capitalised to execute over the next several years","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/17/how-does-bell-potter-rate-these-asx-healthcare-stocks/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/17/how-does-bell-potter-rate-these-asx-healthcare-stocks/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["PYC.AU","BK7094","IMM.AU","BK7067","CXP","BK7508","ONE.AU","BK4194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619114727","title":"BUZZ - US STOCKS ON THE MOVE-Kyivstar Group, Applied Materials, Tevogen Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2619114727","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619114727?lang=en_us&edition=fundamental","pubTime":"2026-03-14 01:54","pubTimestamp":1773424469,"startTime":"0","endTime":"0","summary":"BUZZ - US STOCKS ON THE MOVE-Kyivstar Group, Applied Materials, Tevogen BioWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nL6N4010OX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HBAN","OFRM","BW","WDCX","CRCA","BIAF","KLAR","CMCT","AMAT","RJF","ULTA","LVWR","AIFF","CVNA","CVNY","VACH","CRVS","SVCO","ICRC","CCUP","IBG","TVGN","SANA","ESQ","IMM.AU","CRCO","KYIV","VEON","ISPC","SDHC","ARES","INMD","INDV","ADBG","CVNX","PODD","FITB","AMPY","DOUG","KLC","PAR","CRCD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2619111163","title":"Dr. Reddy's SA Halts TACTI-004 Phase III Study Enrollment","url":"https://stock-news.laohu8.com/highlight/detail?id=2619111163","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619111163?lang=en_us&edition=fundamental","pubTime":"2026-03-14 00:50","pubTimestamp":1773420641,"startTime":"0","endTime":"0","summary":"Dr. Reddy's Laboratories SA, a wholly owned subsidiary of Dr. Reddy's Laboratories Limited, is reassessing its collaboration with Immutep SAS on Eftilagimod alfa after Immutep’s independent data monitoring committee recommended discontinuing the TACTI-004 Phase III first-line non-small cell lung cancer trial following an interim futility analysis. Dr. Reddy's SA has so far made only the upfront payment and is engaging with Immutep on the way forward.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dr. Reddy's Laboratories Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 13, 20","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDL66dqFv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619905531","title":"BRIEF-Dr Reddy's Says IDMC Recommends Discontinuation Of TACTI-004 Phase III Trial After Interim Futility Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2619905531","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619905531?lang=en_us&edition=fundamental","pubTime":"2026-03-13 21:13","pubTimestamp":1773407610,"startTime":"0","endTime":"0","summary":"BRIEF-Dr Reddy's Says IDMC Recommends Discontinuation Of TACTI-004 Phase III Trial After Interim Futility AnalysisMarch 13 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:IDMC RECOMMENDS DISCONTINUATI","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nFWN4010MZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619194169","title":"Immutep Ltd - Trial Discontinued for Futility Based on Safety and Efficacy Data Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2619194169","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619194169?lang=en_us&edition=fundamental","pubTime":"2026-03-13 20:01","pubTimestamp":1773403262,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nFWN40104Y:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","IMM.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":72,"code":"91000000","status":"200"}]}}